vs

Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

Beta Bionics, Inc. is the larger business by last-quarter revenue ($27.6M vs $22.2M, roughly 1.2× FiscalNote Holdings, Inc.). On growth, Beta Bionics, Inc. posted the faster year-over-year revenue change (56.6% vs -24.7%).

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

BBNX vs NOTE — Head-to-Head

Bigger by revenue
BBNX
BBNX
1.2× larger
BBNX
$27.6M
$22.2M
NOTE
Growing faster (revenue YoY)
BBNX
BBNX
+81.3% gap
BBNX
56.6%
-24.7%
NOTE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BBNX
BBNX
NOTE
NOTE
Revenue
$27.6M
$22.2M
Net Profit
$-21.9M
Gross Margin
59.5%
Operating Margin
-47.4%
-83.7%
Net Margin
-79.3%
Revenue YoY
56.6%
-24.7%
Net Profit YoY
23.6%
EPS (diluted)
$-0.49
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBNX
BBNX
NOTE
NOTE
Q1 26
$27.6M
Q4 25
$32.1M
$22.2M
Q3 25
$27.3M
$22.4M
Q2 25
$23.2M
$23.3M
Q1 25
$17.6M
$27.5M
Q4 24
$29.5M
Q3 24
$29.4M
Q2 24
$29.2M
Net Profit
BBNX
BBNX
NOTE
NOTE
Q1 26
$-21.9M
Q4 25
$-13.5M
Q3 25
$-14.2M
$-24.9M
Q2 25
$-16.9M
$-13.3M
Q1 25
$-28.7M
$-4.3M
Q4 24
Q3 24
$-14.9M
Q2 24
$-12.8M
Gross Margin
BBNX
BBNX
NOTE
NOTE
Q1 26
59.5%
Q4 25
59.0%
Q3 25
55.5%
Q2 25
53.8%
Q1 25
50.9%
Q4 24
Q3 24
Q2 24
Operating Margin
BBNX
BBNX
NOTE
NOTE
Q1 26
-47.4%
Q4 25
-50.2%
-83.7%
Q3 25
-62.5%
-43.4%
Q2 25
-85.5%
-31.9%
Q1 25
-105.7%
-50.0%
Q4 24
-19.4%
Q3 24
-23.1%
Q2 24
-27.2%
Net Margin
BBNX
BBNX
NOTE
NOTE
Q1 26
-79.3%
Q4 25
-41.9%
Q3 25
-52.1%
-110.8%
Q2 25
-72.6%
-57.0%
Q1 25
-162.5%
-15.4%
Q4 24
Q3 24
-50.7%
Q2 24
-43.6%
EPS (diluted)
BBNX
BBNX
NOTE
NOTE
Q1 26
$-0.49
Q4 25
$-0.16
$-2.81
Q3 25
$-0.33
$-1.73
Q2 25
$-0.39
$-0.08
Q1 25
$-0.93
$-0.03
Q4 24
$1.88
Q3 24
$-1.33
Q2 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBNX
BBNX
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$199.5M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$271.2M
$62.0M
Total Assets
$304.4M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBNX
BBNX
NOTE
NOTE
Q1 26
$199.5M
Q4 25
$219.1M
$26.3M
Q3 25
$228.7M
$31.2M
Q2 25
$249.7M
$38.5M
Q1 25
$231.5M
$46.3M
Q4 24
$34.6M
Q3 24
$32.7M
Q2 24
$37.7M
Total Debt
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Stockholders' Equity
BBNX
BBNX
NOTE
NOTE
Q1 26
$271.2M
Q4 25
$287.6M
$62.0M
Q3 25
$294.8M
$75.5M
Q2 25
$301.6M
$95.1M
Q1 25
$313.8M
$98.7M
Q4 24
$97.8M
Q3 24
$98.5M
Q2 24
$106.9M
Total Assets
BBNX
BBNX
NOTE
NOTE
Q1 26
$304.4M
Q4 25
$328.7M
$255.1M
Q3 25
$330.0M
$273.9M
Q2 25
$330.0M
$288.3M
Q1 25
$338.0M
$299.7M
Q4 24
$326.2M
Q3 24
$337.9M
Q2 24
$346.3M
Debt / Equity
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
1.54×
Q2 24
1.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBNX
BBNX
NOTE
NOTE
Operating Cash FlowLast quarter
$-279.0K
Free Cash FlowOCF − Capex
$-1.9M
FCF MarginFCF / Revenue
-8.7%
Capex IntensityCapex / Revenue
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
$-8.6M
$-279.0K
Q3 25
$-8.7M
$-8.3M
Q2 25
$-13.6M
$-6.2M
Q1 25
$-20.0M
$3.3M
Q4 24
$-1.3M
Q3 24
$-3.0M
Q2 24
$-3.7M
Free Cash Flow
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
$-10.5M
$-1.9M
Q3 25
$-10.0M
$-10.4M
Q2 25
$-15.4M
$-7.7M
Q1 25
$-20.3M
$1.3M
Q4 24
$-3.4M
Q3 24
$-5.4M
Q2 24
$-6.5M
FCF Margin
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
-32.8%
-8.7%
Q3 25
-36.7%
-46.2%
Q2 25
-66.2%
-33.0%
Q1 25
-115.1%
4.7%
Q4 24
-11.4%
Q3 24
-18.4%
Q2 24
-22.1%
Capex Intensity
BBNX
BBNX
NOTE
NOTE
Q1 26
Q4 25
5.9%
7.4%
Q3 25
4.7%
9.3%
Q2 25
7.7%
6.4%
Q1 25
1.9%
7.2%
Q4 24
6.8%
Q3 24
8.3%
Q2 24
9.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBNX
BBNX

Segment breakdown not available.

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons